New Developments in the Treatment of Retinal Disease

New Developments in the Treatment of Retinal Disease

A/Prof Wilson Heriot
Principal, Eye Surgery Associates, Melbourne

Time: 21 October 2014, 18:00 AEDT (Refreshments from 17:30)

Venue: Mayfield Education, 2-10 Camberwell Rd, Hawthorn East VIC 3123

Biography

Associate Professor Wilson Heriot (MBBS, FRACO, FRACS) is a Principal at Eye Surgery Associates where his clinical practice includes both medical and surgical retina. He is particularly involved in the application of treatment advances in age-related macular degeneration, including the Lucentis drug which was added to the PBS Scheme in Australia in August 2007 is an example of this. Lucentis is applied by injection and, for patients for whom this is appropriate, is having a tremendous impact on their health and well-being.

A/Prof Heriot is chair of the Oceania Retina Association (ORA) and board member of the Macular Degeneration Foundation. He has been a faculty member of the Retina Satellite meetings for the American Academy of Ophthalmology, the Duke Eye Centre and Cleveland Clinic retinal update courses and an invited speaker at a variety of international meetings.

Following completion of his general ophthalmology training in Melbourne, Dr Heriot spent two years in New York conducting research on pigment epithelial phototoxic injury and initiation of choroidal neovascularisation. His subsequent vitreoretinal fellowship with Dr Robert Machemer allowed continued research on pigment epithelial injury and repair. His other research interests have been on the epidemiology of diabetic retinopathy, management of submacular haemorrhage and most recently treatment advances in age-related macular degeneration.